WO1999035245A3 - Methods for preparing and using immortalized human neuroendocrine cells - Google Patents

Methods for preparing and using immortalized human neuroendocrine cells Download PDF

Info

Publication number
WO1999035245A3
WO1999035245A3 PCT/US1999/000553 US9900553W WO9935245A3 WO 1999035245 A3 WO1999035245 A3 WO 1999035245A3 US 9900553 W US9900553 W US 9900553W WO 9935245 A3 WO9935245 A3 WO 9935245A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
immortalized human
human
cell lines
Prior art date
Application number
PCT/US1999/000553
Other languages
French (fr)
Other versions
WO1999035245A2 (en
WO1999035245A9 (en
Inventor
Christopher B Newgard
Karl V Normington
Samuel A Clark
Anice E Thigpen
Christopher Rhodes
Fred Kruse
Original Assignee
Univ Texas
Betagene Inc
Christopher B Newgard
Karl V Normington
Samuel A Clark
Anice E Thigpen
Christopher Rhodes
Fred Kruse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Betagene Inc, Christopher B Newgard, Karl V Normington, Samuel A Clark, Anice E Thigpen, Christopher Rhodes, Fred Kruse filed Critical Univ Texas
Priority to AU22199/99A priority Critical patent/AU2219999A/en
Publication of WO1999035245A2 publication Critical patent/WO1999035245A2/en
Publication of WO1999035245A9 publication Critical patent/WO1999035245A9/en
Publication of WO1999035245A3 publication Critical patent/WO1999035245A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Disclosed are methods of generating immortalized human regulated secretory cells and cell lines of neuroendocrine origin, the immortalized human neuroendocrine cells and cell lines thus generated, and methods of using these human cells, for example, in the production of secretory polypeptides and in cell-based therapeutic methods. Exemplary cells are stable human β-cells that produce insulin. The immortalized human neuroendocrine cells and cell lines are generally prepared by methods using promoters, and preferably tissue-specific promoters, to express immortalizing constructs and, in certain embodiments, by using modified promoters, combinations of immortalizing constructs, viral delivery and defined culture media.
PCT/US1999/000553 1998-01-12 1999-01-11 Methods for preparing and using immortalized human neuroendocrine cells WO1999035245A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22199/99A AU2219999A (en) 1998-01-12 1999-01-11 Methods for preparing and using immortalized human neuroendocrine cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7120998P 1998-01-12 1998-01-12
US60/071,209 1998-01-12
US9110598P 1998-06-29 1998-06-29
US60/091,105 1998-06-29

Publications (3)

Publication Number Publication Date
WO1999035245A2 WO1999035245A2 (en) 1999-07-15
WO1999035245A9 WO1999035245A9 (en) 1999-09-30
WO1999035245A3 true WO1999035245A3 (en) 1999-10-28

Family

ID=26751958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000553 WO1999035245A2 (en) 1998-01-12 1999-01-11 Methods for preparing and using immortalized human neuroendocrine cells

Country Status (2)

Country Link
AU (1) AU2219999A (en)
WO (1) WO1999035245A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144359A0 (en) 1999-01-21 2002-05-23 Vitro Diagnostics Inc Immortalized cell lines and methods of making the same
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
DE10019195B4 (en) * 2000-04-17 2006-03-09 Heart Biosystems Gmbh Reversible immortalization
AU2002235728A1 (en) * 2001-02-26 2002-10-03 Novo Nordisk A/S Method for generating insulin-secreting cells suitable for transplantation
CA2479512C (en) * 2002-03-15 2012-10-16 Laura E. Niklason Tissue engineering
CA2435274A1 (en) * 2002-10-02 2004-04-02 Naoya Kobayashi Immortalized hepatocyte cell line secreting modified insulin with glucose sensitivity
KR20070008714A (en) 2004-04-30 2007-01-17 오르버스네이치 메디칼 인코포레이티드 Medical device with coating for capturing genetically-altered cells and methods of using same
US8741555B2 (en) 2004-05-14 2014-06-03 Organ Recovery Systems, Inc. Apparatus and method for perfusion and determining the viability of an organ
WO2006045105A2 (en) 2004-10-20 2006-04-27 Vitro Diagnostics, Inc. Generation and differentiation of adult stem cell lines
US10176887B1 (en) 2005-11-14 2019-01-08 Organ Recovery Systems, Inc. Ex vivo methods for drug discovery, development and testing
US8765364B2 (en) 2007-05-18 2014-07-01 Lifeline Scientific, Inc. Ex vivo methods for validating substance testing with human organs and/or tissues
US8771930B2 (en) * 2007-05-18 2014-07-08 Lifeline Scientific, Inc. Ex vivo methods for testing toxicity of substances using donated human organs or tissues
CN115011549B (en) * 2022-07-12 2023-08-22 上海交通大学医学院附属仁济医院 Method for establishing gall bladder epithelial cells, gall bladder epithelial cell line and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026321A2 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026321A2 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLARK S A ET AL: "Novel insulinoma cell lines produced by iterative engineering of GLUT2, glucokinase, and human insulin expression [published erratum appears in Diabetes 1997 Oct;46(10):1663].", DIABETES, (1997 JUN) 46 (6) 958-67., XP002112279 *
HOHMEIER H E ET AL: "Regulation of insulin secretion from novel engineered insulinoma cell lines.", DIABETES, (1997 JUN) 46 (6) 968-77., XP002112280 *

Also Published As

Publication number Publication date
WO1999035245A2 (en) 1999-07-15
AU2219999A (en) 1999-07-26
WO1999035245A9 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
WO1999035245A3 (en) Methods for preparing and using immortalized human neuroendocrine cells
IL219969A (en) Cell culture comprising recombinant cho cells that express a factor viii protein
AU2126688A (en) Serum free media for the growth of insect cells and expression of products thereby
WO2001051616A3 (en) Techniques for growth and differentiation of human pluripotent stem cells
AU2009201827B2 (en) Nerve regeneration
AU7945682A (en) Rennin from recombinant dna
AU4336499A (en) Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
WO2005028626A3 (en) Cell culture media
EP0799317B8 (en) Method for secreting thrombopoietin polypeptides
CA2079585A1 (en) Ligand for the neu gene product
AU2369595A (en) In vitro growth of functional islets of langerhans and in vivo uses thereof
GB9822576D0 (en) Membrane
ATE121785T1 (en) METHOD FOR MAINTAINING A DESIRED RECOMBINANT GENE IN A GENETIC CELL POPULATION.
DK1115840T3 (en) Progeny-specific cells and progenitor cells
ATE342275T1 (en) TEMPORARILY IMMORTALIZED CELLS FOR USE IN GENE THERAPY
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
DK0972445T3 (en) Chimeric mouse expressing a human antibody
YU217890A (en) PROCEDURE FOR OBTAINING GENETIC STRUCTURES FOR NERVOUS GROWTH FACTOR EXPRESSION IN EUKARYOTIC CELLS
AU4947500A (en) Process of expressing and isolating recombinant proteins and recombinant proteinproducts from plants, plant derived tissues or cultured plant cells
WO2000077236A3 (en) Methods for enhancing the production of cytokines in cell cultur e
WO2003032923A3 (en) Induction of beta cell differentiation in human cells
WO2002102971A3 (en) Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
ATE311466T1 (en) HUMAN PANCREAS CELL LINES: DEVELOPMENTS AND APPLICATIONS
WO2000006713A3 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
SE0200078D0 (en) Methods for producing and preparing cells for cell therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1; PAGES 1/30-30/30, DRAWINGS, REPLACED BY NEW PAGES 1/30-30/30; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase